Clinical Trial Update: PDE6A Gene Therapy for Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update for PDE6A gene therapy targeting retinitis pigmentosa, indicating ongoing development with active not recruiting status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• PDE6A gene therapy (PDE6A gene therapy)

Snippet

Sponsor: STZ eyetrial | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING